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BACKGROUND: Parvovirus B19 (B19V) is a small,
nonenveloped virus that typically causes a benign flu-
like illness that occurs most frequently in childhood. The
virus is resistant to current viral inactivation steps used
in the manufacture of antihemophilic factor concentrates
and B19V transmission through these products has
been documented. Since 2000, B19V nucleic acid test
(NAT) screening of plasma pools has been imple-
mented to further decrease the viral burden in these
products, but no study has examined populations using
these products to assess the impact of the screening
on B19V transmission.
STUDY DESIGN AND METHODS: Blood specimens
obtained from participants of a surveillance system
established in federally supported specialized bleeding
disorders clinics were used in a B19V seroprevalence
study.
RESULTS: A total of 1643 specimens from 1043 partici-
pants age 2 to 7 years born after B19V NAT screening
was implemented were tested. Age-specific prevalence
rates were generally higher for subjects exposed to
either plasma-derived products alone or in combination
with other products compared to subjects with no expo-
sure to antihemophilic products. Overall, compared to
participants unexposed to blood or blood products,
those exposed to plasma-derived products alone were
1.7 times more likely to have antibodies to B19V
(p = 0.002).
CONCLUSION: These results are consistent with con-
tinued B19V transmission through plasma-derived factor
concentrates. Effective viral inactivation and detection
processes are needed to protect users of these prod-
ucts from infection with B19V or other new or emerging
viruses.
P
arvovirus B19 (B19V) is a ubiquitous small non-
enveloped DNA erythrovirus and infects up to
50% of persons by the age of 15 years.1 Most
persons have only a mild rash as a child or young
adult (erythema infectiosum), and complications are rare.
However, infection during pregnancy can cause fetal
death.2,3 In addition, the infection can produce severe
anemia in persons with hemolytic anemias as well as
acute and subacute joint swelling in as many as 3% to 10%
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of children and up to 50% to 60% of adults, particularly
women.1,4 The development of anti-B19V immunoglobu-
lin (Ig)M may be associated with elevated serologic
variables characteristically associated with rheumatoid
arthritis5 and up to 17% of patients may develop a chronic
arthritis after the infection that is clinically similar to
rheumatoid arthritis.4,6 In fact, B19V has been proposed as
a causative agent for rheumatoid arthritis by some
authors.7-9 One study reported fluctuating levels of anti-
parvovirus IgM in conjunction with disease flare-ups in
children with juvenile rheumatoid arthritis.10
The relatively high prevalence of B19V infection in the
general population combined with the large number of
blood donations used in the manufacture of plasma-
derived factor concentrates virtually assures some con-
tamination.11,12 Resistance to inactivation and elimination
techniques by available virucidal processes has led to the
transmission of B19V by plasma-derived factor replace-
ment products used to treat hemophilia.13,14
In an earlier report, we found that the seroprevalence
of IgG antibodies to B19V was much higher among very
young (age 2-7 years) hemophilia patients exposed to
plasma-derived products compared to those not
exposed.15 B19V seroprevalence among those using only
recombinant products was not elevated above the base-
line rate. In addition, joint range-of-motion (ROM) loss
was greater among subjects who were seropositive com-
pared to those who were seronegative, suggesting that at
least some of the joint disease may have resulted from
B19V delivered intravenously (IV) from contaminated
product. This association was significant after controlling
for the effect of independent variables that included the
number and severity of bleeding events, the total exposure
to factor concentrates, and body mass index (BMI).
The contribution of B19V to the pathogenesis of
hemophilic arthropathy remains unknown. Zakrzewska
and colleagues16 detected B19 DNA in the synovium of 20
of 65 (31%) patients with hemophilic arthropathy ages 34
to 76 years and 5% of controls who underwent synovec-
tomy. Among the 38 patients with hemophilia for whom
serum specimens were available, all showed serologic evi-
dence of B19V infection. The authors postulated that
bleeding in the joints allows the virus to reach the synovial
tissue. Whether the presence of the virus in the joint
incites an inflammatory response that exacerbates hemo-
philic arthropathy remains unknown.
In 2000, manufacturers began voluntary “in-process”
nucleic acid test (NAT) screening of plasma pools for B19V
to ensure the quality of source plasma and solvent/
detergent-treated pooled plasma.17 Plasma minipools
containing more than a threshold concentration of B19V
were withheld from fractionation. There is some evidence
that this process has been effective in reducing transmis-
sion of B19V. For example, in a careful investigation of a
patient with a factor-transmitted infection resulting from
an infusion of product from two lots, B19V was found only
in product from the lot not subjected to NAT screening.18 A
recent Food and Drug Administration (FDA) study com-
paring B19V prevalence in various plasma-derived prod-
ucts before and after the institution of minipool B19V NAT
screening concluded that the process effectively lowered
levels of B19V to fewer than 103 genomic equivalents in all
products and to undetectable levels in 81% of tested lots.19
However, to date there has not been a systematic study of
the effectiveness of this strategy in reducing B19V trans-
missions among recipients of these products.
The continuing availability of blood specimens from
young children with bleeding disorders participating in
a Centers for Disease Control and Prevention (CDC)-
sponsored national surveillance project provided the
opportunity to repeat the earlier seroprevalence study to
determine whether B19V NAT screening has decreased the
risk of B19V transmission in plasma-derived antihemo-
philic factor products. We hypothesized that after institu-
tion of B19V NAT screening, children with bleeding
disorders enrolled in our surveillance project and exposed
to plasma-derived factor concentrate would have a similar
rate of B19V infection and measurable antibodies com-
pared to those not exposed to factor concentrate or those
exposed only to recombinant factor concentrates.
MATERIALS AND METHODS
Since 1998, in collaboration with specialized hemophilia
treatment centers (HTCs) in the United States, CDC has
sponsored a surveillance system called the Universal Data
Collection (UDC) project.20 People with bleeding disor-
ders who receive care in these centers are eligible to par-
ticipate in the surveillance. Demographic, treatment, and
outcome data are collected on all participants by care pro-
viders and a sample of blood is collected for infectious
disease testing and storage for blood safety investigations
at CDC. The surveillance has been approved by the CDC
and all local investigational review boards. All participants
(or parents of minor children) gave informed consent.
Only participants born after January 1, 2001, were eligible
for this study so that any treatment with factor concen-
trates would occur after the implementation of B19V NAT
screening.
Data collection
Data were collected on standardized forms according to
definitions and guidelines provided by CDC. Pertinent to
this study, data collected at enrollment included the
month and year of birth, race/ethnicity, sex, type of bleed-
ing disorder, and whether there had been any previous
exposure to factor concentrates or to blood products
(includes blood plasma or cellular fractions and factor
concentrates prepared from human plasma). At enroll-
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ment and at each subsequent clinic visit, the following
additional data were collected: height, weight, highest
inhibitor titer obtained since the last visit and whether
immune tolerance therapy for an inhibitor was being
used, the number of bleeding episodes in the 6-month
period before the visit, treatment schedule (the last three
items reflective of treatment intensity), names of treat-
ment products used since the last visit, and measure-
ments of the ROM of 10 joints (shoulders, elbows, hips,
knees, and ankles) as a potential indicator of B19V contri-
bution to arthropathy.
For the analysis, age was calculated as of the date of
the blood specimen. Parent-reported race/ethnicity was
categorized as white, black, or other for those not of His-
panic ethnicity; those of Hispanic ethnicity were catego-
rized as Hispanic regardless of race. The type of bleeding
disorder was categorized as hemophilia A, hemophilia B,
von Willebrand disease (VWD), or other (i.e., other factor
deficiencies such as Factor [F]VII, FXI, FXIII).
Height and weight measures were converted to BMI
by dividing weight in kilograms by height in meters
squared. Participants with hemophilia whose highest
inhibitor titer was 1 or more Bethesda unit or who were
receiving immune tolerance therapy were defined as
having a current inhibitor. Patients were categorized as
receiving either episodic (factor infusions in response to a
bleed) or prophylactic (factor infusions on a regular basis
to prevent bleeding) therapy. As a measure of disease
severity, the number of bleeds (according to infusion logs
or parent recall) was categorized as none, one to three, or
four or more bleeds in the previous 6 months. ROM mea-
sures were obtained by trained physical therapists or other
care providers trained and certified in the use of standard
methods detailed in a CDC-provided manual and video.
These measures were used to calculate for each partici-
pant an overall summary measure of joint motion that
reflects the subject’s proportion of normal ROM based on
published reference data.21
Blood samples and testing
Blood specimens were obtained at each UDC visit for eli-
gible subjects. Since subjects could participate annually in
UDC, some participants had multiple specimens avail-
able. Most participants with hemophilia had been
exposed only to recombinant factor concentrates. All
specimens obtained from children unexposed to blood or
antihemophilic factor products and from those exposed
to plasma-derived products were tested. Because the
number of available samples from children who had been
exposed only to recombinant products was far greater
than the number from children with no product exposure
(the reference group), we maximized testing efficiency by
randomly selecting from the recombinant-only group
approximately the same number of samples available in
the age group with the largest number of unexposed
patients (n = 125).
Because acute-phase markers of infection are rela-
tively transient, they were not considered appropriate for
this study. Therefore, all available serum samples from eli-
gible participants were tested for the presence of IgG anti-
B19V using an enzyme-linked immunosorbent assay test
(Biotrin International Ltd, Dublin, Ireland). The test uses
purified recombinant VP2 protein coated wells to detect
the IgG antibodies in human serum or plasma. The high
degree of homology of the VP2 capsid protein between
genotypes results in a high level of antigenic cross-
reactivity between the genotypes; however, the test does
not discriminate between the different genotypes. All
testing was performed according to instructions provided
by the manufacturer and all readings were within
manufacturer-supplied quality control guidelines.
Statistical analysis
Data on lifetime exposure to factor concentrates and
blood products along with the list of all products used
before each clinic visit were used to categorize partici-
pants into one of four exposure groups: 1) subjects with no
exposure to either factor concentrates or blood products,
2) subjects exposed to recombinant factor concentrates
only, 3) subjects exposed to both recombinant and
plasma-derived factor concentrates, and 4) subjects
exposed to plasma-derived factor concentrates only.
Relations between patient demographic and clinical
characteristics and both product exposure category and
B19V seroprevalence were examined using chi-square
tests. The seroprevalence of B19V for each risk subgroup
defined by age and product exposure category was calcu-
lated by dividing the number of patients who tested posi-
tive by the total number of patients tested in each
subgroup. Confidence intervals (CIs) for the prevalence
estimates were calculated according to the efficient score
method (corrected for continuity) described by New-
combe.22 Prevalence estimates for the exposed patient
subgroups that were outside the 95% CIs for the preva-
lence in the unexposed patient subgroup were considered
to be significantly different.
The independent effect of exposure category on B19V
prevalence was assessed for statistical significance using
logistic regression. Prevalence odds ratios (ORs) were
calculated for each exposure category relative to the
subgroup unexposed to factor or blood products from a
regression model that also included variables for age,
sex, race/ethnicity, bleeding disorder, bleeding frequency,
inhibitor status, and year of blood sample.
Finally, the independent effect of B19V positivity on
joint ROM was assessed using a multiple linear regression
model that used the summary ROM measure as the
dependent variable and included all of the terms included
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in the logistic model as well as BMI as independent vari-
ables. All analyses were performed using computer soft-
ware (SAS, Version 9.2, SAS Institute, Cary, NC) and p
values of not more than 0.05 were considered significant.
RESULTS
As of August 2010, there were 1863 eligible UDC partici-
pants who had donated a blood specimen at each of 3970
visits. We excluded specimens from subjects with missing
data on either current product exposures or lifetime expo-
sure to blood or blood products (n = 311) as well as speci-
mens from subjects with exposure to blood or blood
component transfusion only (n = 4). After random selec-
tion of specimens from participants who had been
exposed to recombinant products only, the final study
sample consisted of 1643 specimens from 1043 partici-
pants (Fig. 1). Among the subjects, 61% had one speci-
men, 26% had two specimens, 9% had three specimens,
and 4% had four or more specimens tested.
The demographic and clinical characteristics of the
participants are shown in Table 1. Approximately two-
thirds of participants had hemophilia, nearly one-third
had VWD, and a small proportion had other factor defi-
ciencies. The majority of subjects were male, reflective of
the hemophilia population, while the distribution of race
and ethnicity was similar to that of the population receiv-
ing care in the US HTCs. Two-thirds of the study subjects
were using treatment products only in response to a
hemorrhage, nearly one-half of the subjects had not
experienced a bleeding event in the 6 months before the
clinic visit, and just under 6% had a current hemophilia
inhibitor.
As expected, the distributions of product exposures
varied across most of the patient characteristics (Table 1).
For example, most factor-exposed patients with hemo-
philia used recombinant products whereas those with
VWD used plasma-derived products since recombinant
products contain no von Willebrand factor. This difference
is also reflected in the markedly higher use of plasma-
derived concentrates by females, most of whom had VWD.
The prevalence of B19V antibodies according to
patient characteristics is also shown in Table 1. As
expected, B19V prevalence increased with age but was not
associated with any of the other demographic or clinical
characteristics.
Figure 2 shows the prevalence of B19V antibodies by
age and product exposure category. CIs for the prevalence
among subjects unexposed to factor concentrates indi-
cate the values within which the true prevalence of the
unexposed population lies with a certainty of 95%. The
B19V prevalence values for each age group exposed only
to recombinant products fall within the
CI for each corresponding unexposed
age group (Fig. 2). On the other hand,
the prevalence values for subjects in
four of the six age groups exposed either
to both plasma-derived and recombi-
nant products or to plasma-derived
products alone are higher than the
upper CI boundary for unexposed sub-
jects. Furthermore, among 7-year-olds
exposed to plasma-derived products
only, the prevalence is near the upper
CI boundary for unexposed subjects
(Fig. 2).
Using logistic regression, we
assessed the independent effect of
product exposure on the likelihood of
B19V positivity. After the effects of all
of the patient characteristics as well as
for the year in which the blood sample
was obtained to account for trends
in prevalence rates over time were
adjusted for, the odds of positivity were
70% higher (OR, 1.7; p = 0.002) among
subjects exposed to plasma-derived
products alone relative to those unex-
posed (Table 2). There was no signifi-
cant difference in the odds of positivity
between either of the other product
Exclusions: 
Missing data:  230 
Blood or blood 
components:  2 
Total subjects eligible: 
1863 
Subjects eligible after exclusions: 
1631 
Random selection of 
recombinant only 
subjects:  588 not 
selected 
Total subjects participating: 
1043 
No product
exposure: 
340 
Recombinant
only:
531 
Recombinant/
Plasma-derived:
51 
Plasma-derived
only:
121 
Fig. 1. Subject selection and exclusion algorithm.
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exposure groups compared to the unexposed group. As
expected, the prevalence increased significantly among
older subjects relative to the youngest participants. The
increasing prevalence ORs for subjects tested in later years
of the study provide evidence for population trend of
increasing B19V prevalence in 2008 to 2010 that was sig-
nificant independent of the characteristics of the bleeding
disorders population.
Finally, linear regression was used to evaluate
whether subjects with hemophilia who were B19V positive
had less joint function than those who were B19V
negative. After adjustment for age, number of bleeding
episodes, BMI, and prophylaxis status, there was no sig-
nificant difference in mean summary joint function by
B19V status.
DISCUSSION
Because screening of blood donors can miss infections
during the period between exposure and development of
detectable antibodies, the safety of plasma products rests
on effective viral detection and inactivation or elimina-
tion. In the case of B19V, blood donors can have a high
viremic load without overt signs of infection. In addition,
there is evidence that B19V viremia can persist for years
in healthy individuals.23 These characteristics combined
with a prevalence of B19V of approximately 1% among
blood donors lead to a high probability that plasma pools
will be contaminated.11,12 Because B19V capsid is resistant
to the viral inactivation processes currently used in the
manufacture of plasma derivatives, the strategy of screen-
ing plasma pools for B19V and rejecting from fraction-
ation plasma pools containing a concentration higher
than 1 ¥ 104 genome equivalents per milliliter of B19V
DNA has been implemented by product manufacturers as
a voluntary in-process control step.
Compared with the results from our previous study,24
our current findings suggest that this strategy appears to
have led to decreased transmission of B19V through these
products; however, some transmission continues to occur.
TABLE 1. Characteristics at enrollment of 1043 subjects with bleeding disorders and relations with products
used and B19V serostatus*
Characteristic Total
Product type
Human B19V
positiveNo product Recombinant
Recombinant and
plasma derived Plasma derived
Age (years)
2 129 (12.4) 40 (31.0) 75 (58.1) 5 (3.9) 9 (7.0) 27 (20.9)†
3 159 (15.2) 54 (34.0) 79 (49.7) 5 (3.1) 21 (13.2) 41 (25.8)
4 167 (16.0) 62 (37.1) 77 (46.1) 6 (3.6) 22 (13.2) 65 (38.9)
5 174 (16.7) 63 (36.2) 77 (44.3) 11 (6.3) 23 (13.2) 74 (42.5)
6 192 (18.4) 67 (34.9) 94 (49.0) 7 (3.6) 24 (12.5) 94 (49.0)
7 222 (21.3) 54 (24.3) 129 (58.1) 17 (7.7) 22 (9.9) 121 (54.5)
Race/ethnicity
White 634 (60.8) 222 (35.0) 318 (50.2) 23 (3.6) 71 (11.2) 247 (39.0)
Black 125 (12.0) 33 (26.4) 69 (55.2) 9 (7.2) 14 (11.2) 54 (43.2)
Hispanic 194 (18.6) 63 (32.5) 94 (48.4) 12 (6.2) 25 (12.9) 82 (42.3)
Other 90 (8.6) 22 (24.4) 50 (55.6) 7 (7.8) 11 (12.2) 39 (43.3)
Sex
Male 870 (83.4) 216 (24.8)‡ 528 (60.7) 49 (5.6) 77 (8.9) 355 (40.8)
Female 173 (16.6) 124 (71.7) 3 (1.7) 2 (1.2) 44 (25.4) 67 (38.7)
Bleeding disorder
Hemophilia A 537 (51.5) 58 (10.8)‡ 413 (76.9) 48 (8.9) 18 (3.4) 226 (42.1)
Hemophilia B 141 (13.5) 21 (14.9) 107 (75.9) 3 (2.1) 10 (7.1) 50 (35.5)
VWD 322 (30.9) 233 (72.4) 0 0 89 (27.6) 122 (37.9)
Other§ 43 (4.1) 28 (65.1) 11 (25.6) 0 4 (9.3) 24 (55.8)
Treatment type
Episodic 713 (68.4) 338 (47.4)‡ 246 (34.5) 32 (4.5) 97 (13.6) 285 (40.0)
Prophylaxis 330 (31.6) 2 (0.6) 285 (86.4) 19 (5.8) 24 (7.2) 137 (41.5)
Bleeds in past 6 months
None 462 (44.3) 223 (48.3)‡ 181 (39.2) 15 (3.2) 43 (9.3) 181 (39.2)
1 to 3 363 (34.8) 69 (19.0) 229 (63.1) 14 (3.9) 51 (14.0) 151 (41.6)
4+ 218 (20.9) 48 (22.0) 121 (55.5) 22 (10.1) 27 (12.4) 90 (41.3)
Inhibitor|| status
Current inhibitor 60 (5.8) 0‡ 26 (43.3) 26 (43.3) 8 (13.4) 28 (46.7)
No inhibitor 983 (94.2) 340 (34.6) 505 (51.4) 25 (2.5) 113 (11.5) 394 (40.1)
* Data are reported as number (%). Total does not sum to 100% due to missing data.
† p < 0.05 for differences in the proportion of persons positive for human B19V at baseline across levels of the characteristic by chi-square
test.
‡ p < 0.05 for differences in the distribution of products used across levels of the characteristic by chi-square test.
§ Rare factor deficiencies.
|| Hemophilia patients only.
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We found that young children with bleeding disorders
exposed only to plasma-derived factor concentrates were
70% more likely to have antibodies to B19V than those
unexposed to any products.
While lower than the 7.6 times increased likelihood of
B19V antibodies that we reported among children with
hemophilia who had received plasma-derived products
during the period 1993 to 2001,15 the reason for the
increased seroprevalence among similarly exposed chil-
dren in this cohort born after imple-
mentation of NAT screening of plasma
pools is not clear. An FDA study found
that NAT screening of plasma lowers
B19V levels but does not completely
eliminate the virus.19 The same study
noted that B19V IgG, also present in
plasma pools and shown in other
studies to protect susceptible individu-
als from infection when exposed to
product containing B19V DNA,24 is vir-
tually eliminated from the final product,
apparently by steps in the manufactur-
ing process. It is possible that multiple
exposures to plasma-derived products
contaminated with low levels of B19V
but depleted in B19V IgG may have
caused infections in B19V-naïve sub-
jects that led to the higher prevalence
that we observed among users of these
products.
Because B19V NAT screening was
not initiated at the same time for all
products, it is possible that some
patients may have received product that
had not been screened. For example,
investigation of the product-associated
case identified among UDC participants
in 2001 revealed the source of this infec-
tion was product from a lot manufac-
tured from unscreened plasma.18 Also,
in the FDA study,19 approximately 50%
of the tested lots of recovered plasma
used to make one product during the
period 2001 to 2004 had excessive viral
loads leading the investigators to con-
clude that screening was not being
performed. However, if delayed imple-
mentation of screening alone was
responsible for our findings, we would
have expected to see higher prevalence
rates among persons exposed during
the earlier period of the current study. In
fact, the prevalence was highest for the
years 2008 to 2010 even after adjust-
ment for patient age and other charac-
teristics (Table 2). The latter finding is most likely
explained by the fact that small epidemic outbreaks of
B19V typically occur in the general population at intervals
of a few years.25
In a previous study we demonstrated a decreased
overall level of joint ROM for boys with hemophilia who
were B19V antibody positive compared to those who were
negative.15 We hypothesized that IV infusions of B19V-
contaminated factor during active bleeding in a joint
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Fig. 2. B19V seroprevalence by age and product exposure category.
TABLE 2. Characteristics independently associated with B19V
positivity among 1043 subjects with bleeding disorders
Characteristic OR* (95% CI) p value
Exposure group
None Reference
Recombinant only 1.1 (0.7-1.6) 0.7
Recombinant and plasma derived 1.0 (0.6-1.8) 0.9
Plasma-derived only 1.7 (1.2-2.4) 0.002
Age (years)
2 Reference
3 1.3 (0.8-2.0) 0.001
4 2.0 (1.3-3.1) 0.8
5 2.3 (1.5-3.6) 0.2
6 3.0 (1.9-4.8) <0.001
7 3.2 (2.0-5.2) <0.001
Year specimen drawn
2003 Reference
2004 3.3 (0.7-15.3) 0.7
2005 3.7 (0.8-17.0) 0.9
2006 3.3 (0.7-15.1) 0.6
2007 3.3 (0.7-15.0) 0.6
2008 5.6 (1.2-25.0) 0.005
2009 5.2 (1.2-23.3) 0.03
2010 8.3 (1.8-39.3) <0.001
* ORs from a logistic model that also accounted for differences in the distribution of sex,
race, treatment type, bleeding frequency, and hemophilia inhibitor status.
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could have provided a route for direct inoculation and
synovial infection. Other studies have demonstrated B19V
DNA in the synovial tissues of patients with arthritis but it
is not known whether the virus is causal, exacerbating, or
opportunistic in these cases.26 The pathogenesis of blood-
induced arthropathy in hemophilia includes invasion and
destruction of cartilage by hyperplastic activated synovio-
cytes. In vitro studies have demonstrated that the B19V
capsid mediates fibroblast-like synoviocyte activation27
and that B19V-containing sera induce invasive properties
in normal synoviocytes.28 We found no evidence of
decreased joint ROM among B19V-exposed compared
with unexposed boys with hemophilia in this study.
However, the earlier patient cohort had among its
members a much higher proportion of product-
associated infections that would be more likely to lead to
synovial seeding than infections acquired via the normal
respiratory route. In addition, only approximately 15% of
the boys with hemophilia in the current cohort had been
exposed to plasma-derived products versus 30% in the
previous study.15 Therefore, the lack of difference in joint
mobility between exposed and unexposed hemophilia
patients in the current study might be expected given the
much lower rate of presumed product-associated infec-
tions found in the current patient cohort.
Our study had some limitations that should be con-
sidered when evaluating these results. First, since we had
no information on clinical illness among UDC partici-
pants, it is unknown whether the serologic evidence of
B19V that we measured correlated with a symptomatic
infection. B19V infections that occur during the young age
period represented by the subjects in this study are usually
quite mild and often are undiagnosed. In the absence of
clinical signs of disease it might be questioned whether
the serologic evidence of excess B19V exposure that we
found represents immunologic response to noninfectious
B19V viral particles that may have been present in these
products. We are not aware of any reported evidence that
this phenomenon has occurred with B19V but we cannot
rule out the possibility.
Second, we relied on data collected by care providers
to assign lifetime exposure to blood and blood products
for the subjects in our study. It is possible that some expo-
sures may have been missed or incorrectly recorded. For
example, some patients may have been infected through
undocumented transfusions with blood components.
However, because the participants of this study were very
young and receiving care in specialty care clinics it is likely
that most had received all of their care since birth from the
same care provider who would be likely to have complete
records of these exposures. In any case, there is no reason
to think that such undocumented transfusions would be
more likely to occur in patients that received plasma-
derived concentrates. As another example of exposure
misclassification, if some patients in the unexposed group
had actually used plasma-derived products, this error
would have had a tendency to lower the effect that we
observed. Therefore, to the extent that product exposures
were misclassified, we may have underestimated the
strength of the association between plasma-derived factor
use and B19V exposure.
We were missing complete exposure information for
311 samples from 230 subjects. Based upon the informa-
tion that we did have, 83% of these samples would have
been classified as either unexposed to any product (47%)
or exposed to recombinant product only (36%). When
classified this way, the age-specific B19V prevalence rates
were similar to those reported for subjects with complete
exposure information (results not shown). Therefore, we
do not believe that our results were biased by exclusion of
these samples from the analysis.
The current strategy of B19V NAT plasma minipool
screening may not be completely effective in preventing
transmission of B19V and, more importantly, would not
detect other new or emerging viruses with similar charac-
teristics that could pose a hazard to the users of these
products. For example, a recent study of a cohort of
persons with hemophilia documented transmission
through plasma-derived factor concentrates of a newly
discovered human parvovirus (PARV4) that was most
commonly associated with rashes and exacerbation of
hepatitis.29 This virus, along with other non–lipid-
enveloped viruses such as hepatitis A and E, is also resis-
tant to current viral inactivation steps and would not be
detected by the current NAT screening. It is important to
note that while hepatitis screening implemented in the
1970s resulted in some decreased transmission of HIV
through factor concentrates, it was not until effective viral
inactivation methods were applied to the manufacturing
process in 1985 that the risk of transmission was elimi-
nated.30 Our findings add to the growing body of evidence
that viral inactivation steps effective against these types of
viruses are urgently needed.
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